Corporate Presentation
August 11, 2021
Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These
statements include but are not limited to, statements related to the benefits of Vaxcyte's vaccine candidates; the process and timing of
anticipated future development of Vaxcyte's vaccine candidates, including the timing and submission of an IND application for VAX-24 and the initiation of the VAX-24 Phase 1/2 clinical proof-of-concept study thereafter; the timing and availability of topline data for VAX-24; the ability to complete the manufacturing of the GMP drug product; the achievement of future funding milestones; the use and availability of funds from CARB-X; the initiation of IND-enabling activities for VAX-A1 and the nomination of a final vaccine candidate for VAX-PG; the market opportunity for our vaccines; our expectations regarding the potential benefits, spectrum coverage and immunogenicity of our vaccine candidates; the timing of the initiation, progress and expected results of our preclinical studies, clinical trials and research and development plans; and other statements that are not historical fact. The words "anticipate," "believe," "continue," "could," "designed,"
"estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are based on Vaxcyte's current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte's product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; Vaxcyte's reliance on third-party manufacturers; potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates; the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; sufficiency of cash and other funding to support Vaxcyte's development programs and other operating expenses; and the ongoing COVID-19 pandemic, which could materially and adversely affect Vaxcyte's business and operations. These and other risks are described more fully in Vaxcyte's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward- looking statements contained in this release as a result of new information, future events or changes in its expectations.
2
Vaxcyte Mission Statement
Seeking to improve global health by developing
superior & novel vaccines designed to prevent or treat
some of the most common & deadly infectious
diseases worldwide.
3
Key Corporate Highlights
Next-Generation Vaccine Company - Led by Pneumococcal Conjugate Vaccine (PCV) Franchise
Large Market
Opportunity for PCV
Franchise
Cell-Free
Protein Synthesis
Platform
Disciplined | Robust | Aligned |
Target | Development | Critical |
Selection | Pipeline | Resources |
- Scalable PCV platform enabling broader-spectrumPCVs: VAX-24& VAX-XP
- Lead candidate: VAX-24
- 24-valentPCV with potential to replace SOC
- Anticipated IND filing in Jan-Jun '22(1)
- Anticipated Phase 1/2 data readout in late '22- early '23(1)
- Leverages site- specific conjugation
-
Permits production of
"tough-to-make" antigens - Demonstrated speed, flexibility, and scalability
• | Targets well-defined | • Platform unlocks large |
>$7B market segment | market opportunities: | |
• | Honors well- | - VAX-A1: Novel Group A |
understood PCV MOA | Strep conjugate vaccine | |
• | Leverages established | - VAX-PG: Novel |
surrogate immune | periodontitis therapeutic | |
endpoints and clinical | vaccine | |
pathways |
- Strategic alignment with Lonza (manufacturing)
- Seasoned management team, directors and advisors
- IPO in June 2020
- Cash, cash equivalents and investments of $341.0M at 6/30/21
4 (1) Guidance provided as of August 11, 2021.
Experienced Team, Board of Directors, and Scientific Advisors
Outstanding Track Record in Vaccines and Biopharma
Management Team | Board of Directors | |||||||||
Grant Pickering, MBA | Jim Wassil, MS, MBA | Andrew Guggenhime, | Kurt von Emster | Halley Gilbert | Patrick Heron | |||||
CEO & Co-founder | COO | MBA | Interim Chairman | |||||||
President & CFO | ||||||||||
Peter Hirth, PhD | Robert Hopfner, PhD | Heath Lukatch, PhD | ||||||||
Grant Pickering
Jeff Fairman, PhD | Paul Sauer, MBA | Jane Wright-Mitchell, | Scientific Advisory Board | ||||
VP Research & | SVP PD & Manufacturing | PharmD, JD | |||||
Co-founder | General Counsel | ||||||
Jeff Almond, PhD | Tony Ford-Hutchinson, | Bill Hausdorff, PhD | |||||
PhD
Tom Monath, MD | Emmanuel Walter, | |
MD, MPH | ||
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Vaxcyte Inc. published this content on 11 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2021 20:27:18 UTC.